Munich - Delayed Quote EUR

Compass Pathways PLC (5Y6.MU)

3.5800

0.0000

(0.00%)

At close: April 25 at 8:17:19 AM GMT+2

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Such a dynamic was in evidence with U.K.-based Compass Pathways (NASDAQ: CMPS) this week. On news about a step completed in a clinical trial, the company's shares rose by 13% over the period, according to data compiled by S&P Global Market Intelligence. Compass Pathways, which focuses on psilocybin -- the psychoactive compound found in "magic" mushrooms -- announced Tuesday that it had completed dosing in a late-stage clinical trial.

Motley Fool 15 hours ago

CMPS
Psychedelic: Clearmind completes clinical site initiations for AUD trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships. CLEARMIND COMPLETES SITE INITIATIONS FOR AUD TRIAL: Clearmind Medicine (CMND) announced Wednesday the initiation of its U.S. clinical trial site at the Yale School of Medicine’s Department of Psychiatry. With this initiation, the company has now activated all planned sites for its Phase I/IIa clinical trial in Alcoho

TipRanks 21 hours ago

CMND

CMPS

CYBN
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK, April 22, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on tra

Business Wire 4 days ago

CMPS
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK, March 26, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depressant medications, if necessary, and those eligible will receive a dose of either 25 mg of COMP360 or placebo.

Business Wire last month

CMPS
Psychedelic: Exclusive talk with biotech company Clearmind Medicine

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine (CMND), a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights: PSYCHEDELIC PHARMA: Clearmind is a clinical-stage biotech company that aims to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods

TipRanks last month

CMND

ATAI

GHRS
Psychedelic: atai Life Sciences, NRx report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-t

TipRanks last month

CYBN

ATAI

CMND
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg CO

Business Wire last month

CMPS
Compass Pathways to Participate in Stifel Virtual CNS Forum

LONDON & NEW YORK, March 11, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18th, 2025.

Business Wire last month

CMPS
Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and that COMP360’s differentiated profile positions it as a “transformative” treatment in treatment-resistant depression. The firm believes the current valuation fails to reflect the full scope of its opportunity across multiple large-market psychiatric disorders with COMP360 on track to become a blockbuster treatment, if approved. The firm reiterates a Buy ra

TipRanks last month

CMPS
COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics are […]

Insider Monkey last month

CMPS
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks last month

QNTM

ENVB

CYBN
Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.

GuruFocus.com last month

CMPS
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

CMPS earnings call for the period ending December 31, 2024.

Motley Fool last month

CMPS
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

LONDON & NEW YORK, February 27, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provided an update on recent progress across its business.

Business Wire last month

CMPS
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

LONDON & NEW YORK, February 25, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45th Annual Health Care Conference at 1:10 pm ET on March 3rd, 2025.

Business Wire last month

CMPS
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

LONDON & NEW YORK, February 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025.

Business Wire 2 months ago

CMPS
It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

The Senate voted Thursday to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Investor's Business Daily 2 months ago

MNMD

MRNA

CMPS
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

LONDON & NEW YORK, February 05, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference at 8:40 am ET on February 12th, 2025.

Business Wire 2 months ago

CMPS
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

LONDON & NEW YORK, January 21, 2025--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by

Business Wire 3 months ago

CMPS
Compass Pathways Announces Pricing of Underwritten Offering

LONDON & NEW YORK, January 10, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares ("ADSs") and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant ("ADS Warrant") to purchase one

Business Wire 3 months ago

CMPS

Performance Overview

Return	5Y6.MU	MSCI WORLD (^990100-USD-STRD)
YTD	-7.25%	-2.41%
1-Year	-52.58%	+8.50%
3-Year	-68.87%	+28.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Compass Pathways PLC (5Y6.MU)

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Compass Pathways Announces Pricing of Underwritten Offering

Performance Overview